LPLarisa Prikhodina

Larisa Prikhodina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Larisa Prikhodina has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:

  • Marina Lebedenkova

    Inherited and Acquired Kidney Diseases Research Institute of Pediatrics, Pirogov Russian National Research Medical University Moscow Russian Federation

    5 shared publications
  • Svetlana Papizh

    Veltishev Research Clinical Institute for Pediatrics & Children Surgery, Pirogov Russian National Research Medical University , Moscow

    5 shared publications
  • Elena Levtchenko

    Emma Children’s Hospital, Amsterdam UMC, Location AMC Department of Pediatric Nephrology Amsterdam

    4 shared publications
  • Franz Schaefer

    Center for Pediatrics and Adolescent Medicine, Heidelberg University Hospital , Heidelberg

    4 shared publications
  • Marcin Tkaczyk

    4 shared publications
  • Svetlana V. Papizh

    Veltischev Research and Clinical Institute for pediatrics and pediatric surgery at the Pirogov Russian National Research Medical University

    4 shared publications

Latest Publications

  • Pharmacological monitoring of mycophenolic acid in blood in children with nephrotic syndrome

    by S. L. Morozov, V. A. Obukhova, L. S. Prikhodina, С. Л. Морозов, В. А. Обухова, Л. С. Приходина

    Idiopathic nephrotic syndrome in children is the most common glomerular disease in pediatric practice and frequently requires long-term immunosuppressive therapy because of steroid dependence and frequent relapses. Mycophenolate mofetil has emerged as a preferred steroid-sparing agent in international guidelines due to its favorable safety profile and proven efficacy in reducing relapse rates in steroid-dependent and frequently relapsing nephrotic syndrome in children. Its active metabolite, mycophenolic acid, exhibits marked interindividual pharmacokinetic variability influenced by age, serum albumin, kidney and liver function, concomitant therapies, and genetic factors, which underpins the need for therapeutic drug monitoring. This narrative review summarizes current evidence on the pharmacokinetics and pharmacodynamics of mycophenolic acid in pediatric nephrotic syndrome, focusing on target exposure parameters such as area under the concentration–time curve (AUC) and trough levels (C0) and their association with clinical efficacy and relapse risk. Particular attention is given to limited sampling strategies enabling reliable estimation of mycophenolic acid exposure from a small number of timed blood samples, as well as to population pharmacokinetic modeling as tools to individualize dosing in clinical practice. The potential role of inosine monophosphate dehydrogenase activity as a pharmacodynamic biomarker is discussed, and key gaps are highlighted, including the need for prospective trials to define optimal target exposure ranges for mycophenolic acid in children with steroid-dependent and frequently relapsing nephrotic syndrome.

  • Open Access

    Pathogenesis, clinical and histological features of calcineurin inhibitors induced nephrotoxicity: Literature review

    by A. M. Khokhlova, E. S. Stolyarevich, L. S. Prikhodina, А. М. Хохлова, Е. С. Столяревич, Л. С. Приходина

    Since the 1980s, calcineurin inhibitors (CNI) have been widely used as immunosuppressive agents in solid organ transplantation and in the treatment of immune-mediated glomerular diseases, including complicated nephrotic syndrome. However, CNI-induced nephrotoxicity (CNIT) remains one of the most frequent adverse effects of this treatment. Despite the long-term usage of CNI in clinical practice, data on this side effect are limited. This review summarizes the available literature on the pathogenesis, clinical manifestations, and histologic characteristics of acute and chronic CNIT. The clinical manifestations of CNIT are variable because CNIs can affect all compartments of the kidney, including glomeruli, arterioles, and tubulointerstitium. An increase in serum creatinine from baseline is currently the principal routinely used clinical marker of CNIT. Acute CNIT results predominantly from functional hemodynamic changes, is typically dose-dependent, and may be reversible following dose reduction or discontinuation of CNI therapy. Nevertheless, preventive measures may not always avert the development of chronic CNI-induced nephropathy, which is characterized by structural changes in the kidney tissue and occurs in a considerable proportion of patients receiving long-term treatment. Awareness of the complex pathogenesis and diversity of clinical manifestations of CNI-mediated kidney injury may facilitate the timely recognition and management of acute CNIT and help prevent its progression to chronic kidney damage.

  • Open Access

    A multi-national study examined the response sustainability to calcineurin inhibitors and long-term kidney survivals in children with genetic podocytopathies

    by Georgia Malakasioti, Daniela Iancu, Chun Ting Au, Dongyang Zhou, Anastasiia Milovanova, Alexey Tsygin, Tomoko Horinouchi, China Nagano, Kandai Nozu, Koichi Kamei, et al.

  • The European distal renal tubular acidosis registry: a 5-year analysis

    by Marta Giaccari, Faidra Veligratli, Wesley Hayes, Rezan Topaloglu, Gulsah Ozdemir, Barbara Ruggiero, Olivia Boyer, Bertrand Knebelmann, Yann Nedelec, Marc Fila, et al.

    Background: Distal renal tubular acidosis (dRTA) is characterized by metabolic acidosis, growth failure, nephrocalcinosis, nephrolithiasis and chronic kidney disease (CKD). Previous retrospective data suggested improved outcome with adequate metabolic control, but confirmation from prospective data is lacking. Since 2019, the European dRTA registry has collected prospective data on patients with dRTA. Herein we present results of the first data analysis. Methods: The registry is hosted as a subregistry of the European Rare Kidney Disease Network (https://www.erknet.org/). In addition to the standard items of growth and plasma creatinine, additional data on plasma and urine biochemistries, genetics, treatment and clinical manifestations were collected from February 2019 through May 2024. Logistic regression analysis was used to identify predictors of CKD and impaired growth. Results: Of the 214 patients enrolled in the registry, only 22% were aged >18 years at the last visit. A genetic diagnosis was documented in 69% of patients. On average, low blood bicarbonate levels (30 years had significantly lower estimated glomerular filtration rate (P < .001) and the overall prevalence of CKD stage ≥2 was 36%. Patients with SLC4A1 variants were at higher risk of CKD stage >1 (P = .013). Conclusion: Our results in this primarily paediatric cohort highlight the importance of metabolic control and support increasing the blood bicarbonate level for therapy to 24 mmol/L to improve growth. Compared with the overall population, patients with dRTA are at higher risk of CKD from childhood, particularly if they have underlying SLC4A1 variants.


  • Kidney damage in tuberous sclerosis

    by S. L. Morozov, O. R. Piruzieva, L. S. Prikhodina

    Tuberous sclerosis is a rare genetic disease characterized by the development of benign tumors in various organs, including the kidneys. Renal lesions in tuberous sclerosis are most often represented by angiomyolipomas and cysts, which can lead to various complications, such as bleeding, renal failure and malignant transformation. This review article examines current concepts of the pathogenesis, clinical manifestations, diagnostics and treatment methods of renal lesions in tuberous sclerosis, as well as prospects for further research in this area.

  • Open Access

    LMX1B-associated steroid-resistant nephrotic syndrome with focal segmental glomerulosclerosis (case report)

    by Larisa S. Prikhodina, Ekaterina S. Stolyarevich, Patricia E. Povilaitite

    Pathogenic variants in the LMX1B gene cause nail-patella syndrome, characterized by dysplasia of the patella, nails and elbows, and renal damage with focal segmental glomerulosclerosis (FSGS) with specific ultrastructural lesions of the glomerular basal membrane (GBM). We present a clinical observation of a girl with LMX1B-associated steroid-resistant nephrotic syndrome without the extrarenal characteristic of nail-patella syndrome with specific ultrastructural changes of the GBM. The presented clinical observation emphasizes the necessity to exclude proteinuria in family members with a child with FSGS and to perform molecular genetic study in all children with FSGS before prescribing immunosuppressive therapy with inclusion of LMX1B gene even in case of isolated kidney pathology.

  • Open Access

    Dent disease: clinical practice recommendations

    by Arend Bökenkamp, Gema Ariceta, Detlef Böckenhauer, Olivier Devuyst, Francesco Emma, David van Bennekom, Elena Levtchenko, John Sayer, Aude Servais, Rosa Vargas, et al.

    Dent disease is a rare X-linked tubulopathy that is characterized by low-molecular-weight proteinuria associated with hypercalciuria, which may lead to nephrolithiasis, nephrocalcinosis, and kidney failure between the third and fifth decades of life in 30%–80% of affected males. The disease is most often associated with various manifestations of proximal tubular dysfunction. Affected individuals may present nephrotic-range proteinuria which may be misinterpreted and cause diagnostic delay. Due to its rarity, there is limited evidence to guide diagnosis and management. These clinical practice recommendations summarize the current knowledge on Dent disease and provide guidance for diagnosis and management. The recommendations are based on a systematic search of the literature and were endorsed by a Delphi procedure among stakeholders in the field as well as the respective ERA and ESPN working groups.


  • Open Access

    An international, multi-center study evaluated rituximab therapy in childhood steroid-resistant nephrotic syndrome

    by Eugene Yu-Hin Chan, Aditi Sinha, Ellen L.M. Yu, Naureen Akhtar, Andrea Angeletti, Arvind Bagga, Sushmita Banerjee, Olivia Boyer, Chang-Yien Chan, Anna Francis, et al.


  • Open Access

    In memory of Vladimir Viktorovich Dlin (05.10.1954-15.02.2024)

    by L. S. Prikhodina

    Длин Владимир Викторович (05.10.1954-15.02.2024)

  • Spectrum of clinical manifestations of X-linked Alport syndrome in girls: a single-center cohort study

    by M.E. Aksyonova, N.E. Konkova, O.R. Piruzeyeva, T.V. Lepayeva, T.A. Nikishina, V.A. Obukhova, L.S. Prikhodina

    X-linked Alport syndrome (XLAS) is an inherited disorder caused by genetic variants in gene COL4A5. The frequency and the severity of clinical manifestations as well as the risk of glomerulopathy progression are variable in XLAS in females, and the disease course features have not been sufficiently studied as yet. Since patient management tactics is determined by the disease course nature, studying the spectrum of XLAS clinical manifestations and prognosis in girls remains relevant. The purpose of this research was to determine the spectrum and the features of clinical manifestations of XLAS in girls. Materials and methods used: a single-center cohort prospective study was carried out by the Authors that included 74 girls aged 2 to 17 y/o with genetically proven XLAS diagnosis. Authors have analyzed the patients’ medical records identifying sensorineural hearing loss (SNHL), arterial hypertension (AH; blood pressure (BP) over 95% than at the patient’s age/height), albuminuria (Alb; norm<30 mg/mmol of creatinine), proteinuria (Pr; norm<100 mg/sq m/day) - with its degree, decrease in estimated glomerular filtration rate (eGFR, ml/min/1.73 sq m; norm≥90 ml/min/1.73 sq m) and angiotensin-converting enzyme inhibitors (ACEIs) therapy data. Results: all patients had hematuria with episodical macrohematuria in 27% of cases, proteinuria in 40%, eGFR decrease in 15%, SNHL in 8% and peripheral retinopathy in 7%. Girls with missense v. those with non-missense variants of COL4A5 more often had macrohematuria (0.15 v. 0.05; p=0.015) and albuminuria (1 v. 0.5; p<0.001) whilst no statistically significant difference was showed in proteinuria frequency and age of onset (0.48 v. 0.5 and 6.5 [3; 11] v. 5 [5; 8] y/o), eGFR decrease (0.15 v. 0.15; 12.4±2.6 v. 13.2 ±2.8 y/o), SNHL (0.07 v. 0.1; 13±2.8 v. 14.4±3.1 y/o) and retinopathy (0.04 v. 0.15; 14.3±3.5 v. 12.6±2.9 y/o). ACEIs therapy did not show any statistically significant effect on the cumulative proportion of patients with both proteinuria and eGFR decrease (log-rank test=1.25, p=0.213 and log-rank test=0.66, p=0.512, respectively). Conclusion: the results obtained demonstrate the need for a dynamic follow-up of girls with XLAS with the purpose of earliest possible detection of proteinuria and timely prescribing with nephroprotective therapy as well as hearing loss diagnosing and timely audiological correction.